Cencora Inc. (COR) showcased consistent financial performance with reports of strong revenue growth and adjusted earnings per share exceeding expectations. Despite the turbulent market, Cencora attained a new 52-week high, declaring increased dividends, consequently attracting value investors. In a strategic move, Cencora secured a $1.5 billion term loan and expanded its specialty business with a $4.6 billion acquisition of Retina Consultants of America. This acquisition is expected to further augment its earnings per share (EPS) growth. However, insider selling by Steven H Collis, who offloaded $12.2 million worth of Cencora stock, brought some uncertainty to potential investors. CreativeOne Wealth LLC and other firms like Zurcher Kantonalbank Zurich Cantonalbank and Vinva Investment Management Ltd increased their stakes in Cencora. Despite the stock price nosediving once, it rebounded quickly and hit a fresh high, signaling potential for further growth. Yet, with medical stocks seemingly lagging compared to Cencora, investors must consider the broader market landscape. The Walgreens Boots Alliance proceeded to sell a chunk of Cencora’s shares, but advocates suggest this decrease in alliance stake shouldn’t alarm investors.
Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 30 Nov 2024 16:02:56 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor 0
